(Cell 182, 843–854.e1–e12; August 20, 2020) We discovered that values for 2 out of 79 antibodies have unfortunately been wrongly reported. For antibody FnC1t1p2_A5, the IC100 is 50 μg/mL instead of 16 μg/mL; for antibody CnC2t1p1_B10, the IC100 is >100 μg/mL instead of 12.5 μg/mL. For the latter antibody, binding characteristics were also corrected. As a consequence, the total number of neutralizing antibodies reported is 27 instead of 28. Changes affect Figures 3, 4, S3, S4, and S5, Tables S3 and S4, and text on pages 1, 3, 5, and 7. Importantly, the corrections have no impact on the conclusions in this paper. We apologize for any inconvenience that may have been caused by this error.Figure 3Infected individuals can develop potent near-germline SARS-CoV-2-neutralizing antibodies that preferentially bind to the S-protein RBD (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 4Dynamics of somatic mutations for SARS-CoV-2-specific antibodies (corrected)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 4Dynamics of somatic mutations for SARS-CoV-2-specific antibodies (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S3Correlation of binding and neutralization with VH gene characteristics (corrected)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S3Correlation of binding and neutralization with VH gene characteristics (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S4VL gene distribution in non-neutralizing and neutralizing antibodies (corrected)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S4VL gene distribution in non-neutralizing and neutralizing antibodies (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S5Autoreactivity of selected SARS-CoV-2-binding and -neutralizing antibodies (corrected)View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S5Autoreactivity of selected SARS-CoV-2-binding and -neutralizing antibodies (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 PatientsKreer et al.CellJuly 7, 2020In BriefIn a longitudinal analysis of SARS-CoV-2-infected people, Kreer et al. find highly potent neutralizing antibodies that use a broad spectrum of variable (V) genes and show low levels of somatic mutations. They also identify potential precursor sequences of these SARS-CoV-2-neutralizing antibodies from virus-naive individuals, sampled before the COVID-19 pandemic. This could indicate that neutralizing antibodies can be readily generated from existing germline antibody sequences found in the general population. Full-Text PDF Open Access
No takes yet. Share an insight, caveat, or question.
Kreer et al. (2020) studied this question.